ACR: Can Tanezumab Be Revived for OA? Low incidence of rapidly progressive OA seen with lower doses CHICAGO -- The monoclonal antibody tanezumab, which blocks nerve growth factor, showed significant benefits in pain and function among patients with osteoarthritis (OA) of the knee or hip, and rates of severe adverse joint events such as rapidly progressive OA that had plagued earlier studies were low, a researcher reported at the annual meeting of the American College of Rheumatology here.
12th International Conference on Orthopedics, Trauma & Rheumatology